Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Now that Biogen Inc.'s ( BIIB , Financial) Alzheimer's treatment has received the Food and Drug Administration's approval, who's next?

Does Eli Lilly Have the Next Big Alzheimer's Drug?

Goldman Sachs

Eli Lilly and Company (LLY) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

The stock price of Eli Lilly & Company (NYSE: LLY) has seen a large 10% rise in a single trading session yesterday. This move came after Biogen's Aduhelm was approved by the U.S. FDA for the treatment of Alzheimer's disease.

Can The Rally Continue For Eli Lilly Stock After A 10% Rise On Increased Hopes For Its Alzheimer's Drug

Annovis Bio

Cassava Sciences Inc

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

Biogen's stunning win of FDA approval for aducanumab spurred investors' excitement about Lilly's prospects for its Alzheimer's disease candidate.

Why Eli Lilly Stock Soared Today

INDIANAPOLIS, June 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO). Lilly is presenting an exploratory analysis from the positive Phase 3 monarchE trial evaluating Verzenio, a CDK4/6 inhibitor, in a subgroup of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC) who had received neoadjuvant chemotherapy.

Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting

INDIANAPOLIS, June 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice president and president, Lilly Oncology and Jake Van Naarden, CEO, Loxo Oncology at Lilly, will participate in a virtual fireside chat on Wednesday, June 9 at 8:50 a.m.

Lilly to Participate in Goldman Sachs Healthcare Conference

The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY) Tyvyt (sintilimab injection) in non-small cell lung cancer (NSCLC). The approval is for expanded use of Tyvyt in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).

Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China

INDIANAPOLIS, June 3, 2021 /PRNewswire/ -- To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the American Headache Society (AHS) 2021 Virtual Annual Scientific Meeting, June 3-6. New findings from OVERCOME (U.S.) revealed the top six reasons why people hesitate to seek migraine care.1 Real-world data insights revealed greater adherence and persistence for Emgality® (galcanezumab-gnlm), a calcitonin gene-related peptide monoclonal antibody (CGRP mAb), compared to oral standard of care (non-CGRP mAb) preventive migraine treatments in a healthcare claims study and greater probability of patient preference for the Emgality auto-injector profile compared to Aimovig® (erenumab) and AJOVY® (fremanezumab) device characteristics in a survey.2,3 In the first pairwise comparison network meta-analysis (NMA) for the acute treatment of migraine comprehensive of the totality of literature available to date, people taking 100 mg and 200 mg doses of REYVOW® (lasmiditan) C-V had greater odds of early onset of efficacy compared to those taking Nurtec® (rimegepant) or UBRELVY® (ubrogepant).4 "People with migraine want and need rapid and complete freedom from migraine.

Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021

SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (NYSE: LLY) today jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). This is the third NMPA-approved indication of TYVYT® (sintilimab injection), following the approval in December 2018 for the treatment of relapsed or refractory classical Hodgkin's lymphoma, and the approval in February 2021 for the first-line treatment of nonsquamous non-small cell lung cancer (nsqNSCLC).

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients. Discovered by Incyte Corporation (NASDAQ: INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults.

Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial

Incyte

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to HUMIRA® (adalimumab) and placebo. These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz® (ixekizumab) among patients with axial spondyloarthritis (axSpA). These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study

Regeneron Pharmaceuticals

The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday.

U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment

Eli Lilly disclosed in a securities filing that it had received a subpoena from the U.S. Department of Justice for documents related to a key company manufacturing site in Branchburg, New Jersey.

Eli Lilly Says It Received DOJ Subpoena

The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE: LLY) focused on alleged manufacturing irregularities and records tampering at Branchburg plant, reports Reuters. The plant manufactures Eli Lilly's COVID-19 therapy and other drugs, three people familiar with the matter said.

Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters

The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant's COVID-19 therapy and other drugs, three people familiar with the matter said.

Exclusive: U.S. opens criminal probe into alleged lapses at Eli Lilly plant - sources

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Lilly (LLY) Up 11.3% Since Last Earnings Report: Can It Continue?

Eli Lilly and Co (NYSE: LLY) has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab, reports Reuters. The subpoena requested certain documents relating to its site in Branchburg, New Jersey.

Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters

Eli Lilly and Co has received a subpoena from the U.S. Department of Justice, requesting certain documents relating to its manufacturing site in Branchburg, New Jersey, the drugmaker said in a filing on Thursday.

U.S. issues subpoena to Eli Lilly over New Jersey manufacturing plant

Eli Lilly and Company's (LLY) Management on UBS Global Healthcare Virtual Conference - Transcript

Getting rich is as simple as buying and holding for the long haul.

Here's How You Can Earn $10,000 a Year in Retirement

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)

Pfizer

Johnson & Johnson

Capital is flowing once more into healthcare stocks. These companies are three of the best components of the sector for investors to buy now.

3 Healthcare Stocks to Buy as the Sector Breaks Out

As a part of a pre-specified analysis of the Phase 2 SERENITY study, new data showed that Eli Lilly And Co's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks. Improvements were sustained up to one year.

News for Eli Lilly Stock (LLY)